169 related articles for article (PubMed ID: 35538636)
21. A Randomized Study of Lenvatinib 18 mg vs 24 mg in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer.
Brose MS; Panaseykin Y; Konda B; de la Fouchardiere C; Hughes BGM; Gianoukakis AG; Joo Park Y; Romanov I; Krzyzanowska MK; Leboulleux S; Binder TA; Dutcus C; Xie R; Taylor MH
J Clin Endocrinol Metab; 2022 Feb; 107(3):776-787. PubMed ID: 34664662
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis.
Zhu C; Ma X; Hu Y; Guo L; Chen B; Shen K; Xiao Y
Oncotarget; 2016 Jul; 7(28):44545-44557. PubMed ID: 27329593
[TBL] [Abstract][Full Text] [Related]
23. Real-life use of lenvatinib in patients with differentiated thyroid cancer: experience from Argentina.
Jerkovich F; Califano I; Bueno F; Carrera JM; Giglio R; Abelleira E; Pitoia F
Endocrine; 2020 Jul; 69(1):142-148. PubMed ID: 32253682
[TBL] [Abstract][Full Text] [Related]
24. Association between baseline blood pressure and the incidence of lenvatinib-induced hypertension in patients with thyroid cancer.
Shibutani Y; Tajiri K; Suzuki S; Enokida T; Sagara A; Okano S; Fujisawa T; Sato F; Yumoto T; Sano M; Kawasaki T; Tahara M
Cancer Med; 2023 Nov; 12(22):20773-20782. PubMed ID: 37902136
[TBL] [Abstract][Full Text] [Related]
25. Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction.
Sueta D; Suyama K; Sueta A; Tabata N; Yamashita T; Tomiguchi M; Takeshita T; Yamamoto-Ibusuki M; Yamamoto E; Izumiya Y; Kaikita K; Yamamoto Y; Hokimoto S; Iwase H; Tsujita K
Atherosclerosis; 2017 May; 260():116-120. PubMed ID: 28390289
[TBL] [Abstract][Full Text] [Related]
26. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
27. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
[No Abstract] [Full Text] [Related]
28. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.
Haddad RI; Schlumberger M; Wirth LJ; Sherman EJ; Shah MH; Robinson B; Dutcus CE; Teng A; Gianoukakis AG; Sherman SI
Endocrine; 2017 Apr; 56(1):121-128. PubMed ID: 28155175
[TBL] [Abstract][Full Text] [Related]
29. Long-term management of lenvatinib-treated thyroid cancer patients: a real-life experience at a single institution.
Porcelli T; Luongo C; Sessa F; Klain M; Masone S; Troncone G; Bellevicine C; Schlumberger M; Salvatore D
Endocrine; 2021 Aug; 73(2):358-366. PubMed ID: 33537956
[TBL] [Abstract][Full Text] [Related]
30. [Lenvatinib in radioiodine refractory thyroid carcinomas].
de la Fouchardiere C
Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
[TBL] [Abstract][Full Text] [Related]
31. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
[TBL] [Abstract][Full Text] [Related]
32. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
[TBL] [Abstract][Full Text] [Related]
33. Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer.
Giani C; Valerio L; Bongiovanni A; Durante C; Grani G; Ibrahim T; Mariotti S; Massa M; Pani F; Pellegriti G; Porcelli T; Salvatore D; Tavarelli M; Torlontano M; Locati L; Molinaro E; Elisei R
Thyroid; 2021 Feb; 31(2):224-232. PubMed ID: 32907501
[No Abstract] [Full Text] [Related]
34. Lenvatinib: a new option for the treatment of advanced iodine refractory differentiated thyroid cancer?
Lorusso L; Newbold K
Future Oncol; 2015; 11(12):1719-27. PubMed ID: 26075440
[TBL] [Abstract][Full Text] [Related]
35. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Ye X; Zhu Y; Cai J
J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic analysis of hypertension caused by lenvatinib using real-world postmarketing surveillance data.
Otani Y; Kasai H; Tanigawara Y
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):188-198. PubMed ID: 33471960
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
38. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
[TBL] [Abstract][Full Text] [Related]
39. Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)
Gaspar N; Campbell-Hewson Q; Gallego Melcon S; Locatelli F; Venkatramani R; Hecker-Nolting S; Gambart M; Bautista F; Thebaud E; Aerts I; Morland B; Rossig C; Canete Nieto A; Longhi A; Lervat C; Entz-Werle N; Strauss SJ; Marec-Berard P; Okpara CE; He C; Dutta L; Casanova M
ESMO Open; 2021 Oct; 6(5):100250. PubMed ID: 34562750
[TBL] [Abstract][Full Text] [Related]
40. Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer: A Snapshot of Real-life Clinical Practice.
Nervo A; Gallo M; Samà MT; Felicetti F; Alfano M; Migliore E; Marchisio F; Berardelli R; Arvat E; Piovesan A
Anticancer Res; 2018 Mar; 38(3):1643-1649. PubMed ID: 29491097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]